Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, Chinot O, Ducray F, Roth P, McDonald K, Hau P, Hottinger AF, Reijneveld J, Schnell O, Marosi C, Glantz M, Darlix A, Lombardi G, Krex D, Glas M, Reardon DA, van den Bent M, Lefranc F, Herrlinger U, Razis E, Carpentier AF, Phillips S, Rudà R, Wick A, Tabouret E, Meyronet D, Maurage CA, Rushing E, Rapkins R, Bumes E, Hegi M, Weyerbrock A, Aregawi D, Gonzalez-Gomez C, Pellerino A, Klein M, Preusser M, Bendszus M, Golfinopoulos V, von Deimling A, Gorlia T, Wen PY, Reifenberger G, Weller M (2023)

Publication Type: Journal article

Publication year: 2023


Book Volume: 189

Article Number: 112913

DOI: 10.1016/j.ejca.2023.05.002


Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24–78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.

Authors with CRIS profile

Involved external institutions

University of California San Francisco (UCSF) US United States (USA) (US) Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino IT Italy (IT) Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV) CH Switzerland (CH) Universitätsspital Zürich (USZ) CH Switzerland (CH) Heinrich-Heine-Universität Düsseldorf DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Aix-Marseille University / Aix-Marseille Université FR France (FR) Hospices Civils de Lyon (CHU) FR France (FR) University of New South Wales (UNSW) AU Australia (AU) Universitätsklinikum Regensburg DE Germany (DE) Vrije Universiteit Amsterdam (VU) / University Amsterdam NL Netherlands (NL) Universitätsklinikum Freiburg DE Germany (DE) Medizinische Universität Wien AT Austria (AT) Penn State Milton S. Hershey Medical Center US United States (USA) (US) University of Montpellier / Université Montpellier FR France (FR) Istituto Oncologico Veneto (IOV), IRCCS IT Italy (IT) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Dana–Farber Cancer Institute US United States (USA) (US) Erasmus University Medical Center (MC) NL Netherlands (NL) Brussels University Hospital (H.U.B) / Hôpital Universitaire de Bruxelles BE Belgium (BE) Rheinische Friedrich-Wilhelms-Universität Bonn DE Germany (DE) Hygeia Hospital GR Greece (GR) Université Sorbonne Paris Cité FR France (FR) Centre de recherche en cancérologie FR France (FR) Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille) FR France (FR) Stichting Epilepsie Instellingen Nederland (SEIN) NL Netherlands (NL) Universitätsklinikum Heidelberg DE Germany (DE) European Organisation for Research and Treatment of Cancer (EORTC) BE Belgium (BE)

How to cite


Hertler, C., Felsberg, J., Gramatzki, D., Le Rhun, E., Clarke, J., Soffietti, R.,... Weller, M. (2023). Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). European Journal of Cancer, 189. https://doi.org/10.1016/j.ejca.2023.05.002


Hertler, Caroline, et al. "Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)." European Journal of Cancer 189 (2023).

BibTeX: Download